(Q41483397)

1 October 2017

1 reference

title

Gemcitabine in ovarian cancer: an overview of safety and efficacy (English)

1 reference

1 October 2017

1 reference

M Kaufmann

1

1 reference

1 October 2017

G von Minckwitz

series ordinal

2

1 reference

1 October 2017

publication date

1 January 1997

1 reference

European Journal of Cancer

1 October 2017

published in

1 reference

1 October 2017

volume

33 Suppl 1

1 reference

1 October 2017

page(s)

S31-3

1 reference

Current concepts in cancer: ovary--treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors.

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900338-3

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900338-3

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900338-3

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900338-3

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900338-3

7 January 2021

Safety profile of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900338-3

7 January 2021

10.1016/S0959-8049(96)00338-3

Identifiers

DOI

1 reference

1 October 2017

1 reference